FDA Approves At-Home Use of BioXcel Agitation Drug

The US Food and Drug Administration approved at-home use of BioXcel Therapeutics drug Igalmi for agitation tied to schizophrenia or bipolar disorder. Teva Pharmaceuticals acquired the asset and will announce commercialization plans later.

Xurve View
Insights:
FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020.

The United States Food and Drug Administration cleared at-home use of BioXcel Therapeutics' Igalmi for agitation linked to schizophrenia or bipolar disorder on Monday afternoon. The expanded approval creates a first-of-its-kind outpatient treatment option without requiring healthcare provider supervision. Investors gain a clearer commercial outlook after asset ownership transferred to a unit of TEVA PHARMACEUTICAL-SP ADR.